Effects of Bardoxolone Methyl on Magnesium in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease

BACKGROUND: Treatment with bardoxolone methyl (Bard) in a multinational phase 3 trial, Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes (BEACON), resulted in increases in estimated glomerular filtration rate with concurrent reductions in serum magnesium. We a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cardiorenal Med
Main Authors: Rizk, Dana V., Silva, Arnold L., Pergola, Pablo E., Toto, Robert, Warnock, David G., Chin, Melanie P., Goldsberry, Angie, O'Grady, Megan, Meyer, Colin J., McCullough, Peter A.
Formato: Artigo
Idioma:Inglês
Publicado em: S. Karger AG 2019
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6751480/
https://ncbi.nlm.nih.gov/pubmed/31170712
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000500612
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados